Public-private partnership tackles TB challenges in parallel.
The Global Alliance for TB Drug Development and Tibotec have joined forces to develop a potential first-in-class drug for both drug-susceptible and drug-resistant tuberculosis.
Webb
Sarah
S
D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003299:Cooperative Behavior; D064687:Diarylquinolines; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009939:Organizations, Nonprofit / Q000458:organization & administration; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D064687:Diarylquinolines; D011804:Quinolines; C493870:bedaquiline